Clinical trial
A Phase 1b Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers (TCEs) in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoid (R/R B-Cell NHL) Malignancies
NCT06660563 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers (TCEs) in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoid (R/R B-Cell NHL) Malignancies
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 22, 2024
- Completion date
- March 31, 2027
- Enrollment
- 19 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.